Cannabis Report
Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

IPIX RSS Feed
Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: LilKahuna, BooDog, sox040713, Astavakra, 123tom, scottsmith
Search This Board: 
Last Post: 7/22/2018 8:22:38 PM - Followers: 758 - Board type: Free - Posts Today: 53

Innovation Pharmaceuticals Inc. (IPIX)

https://www.sec.gov/Archives/edgar/data/1355250/000147793217002710/ctix_8k.htm
 

http://www.ipharminc.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@ipharminc.com

 
About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' psoriasis drug candidate Prurisol completed a Phase 2 trial and Innovation Pharmaceuticals is nearing completion of a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at http://www.ipharminc.com.

Management: http://www.cellceutix.com/senior-management/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://www.ipharminc.com/therapeutic-areas/

 

PIPELINE: 

FDA DESIGNATIONS:

2017 MILESTONES:



Recent News and Press Releases: 
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/

 
SEC Filings (CIK:0001355250): 
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 

http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1


Following is a DAILY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

Cannabis Report
IPIX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IPIX News: Current Report Filing (8-k) 06/29/2018 02:11:50 PM
IPIX News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 06/29/2018 07:24:52 AM
IPIX News: Quarterly Report (10-q) 05/10/2018 04:14:20 PM
IPIX News: Traders News Issues Research on High Growth Canna and Pharma Stocks 04/25/2018 08:00:00 AM
IPIX News: Current Report Filing (8-k) 04/16/2018 01:18:08 PM
PlusOneCoin Top Posts
#235017   I'm thinking that what you are referring to KarinCA 07/22/18 10:15:51 AM
#232970   With PRU Dbase lock announced -- countdown on slcimmuno 06/30/18 01:19:32 PM
#235000   IPIX Milestones, Clinical Trials, Recent Articles, Corporate Overview, Patent sox040713 07/21/18 11:52:18 PM
PostSubject
#235000  Sticky Note IPIX Milestones, Clinical Trials, Recent Articles, Corporate Overview, Patent sox040713 07/21/18 11:52:18 PM
#234839  Sticky Note For Aspire, it’s not a bet. It’s James LilKahuna 07/19/18 08:48:03 AM
#234598  Sticky Note Was this one of the milestones? This scottsmith 07/17/18 07:59:19 AM
#234577  Sticky Note Most IPIX investors feel pretty confident that Brilacidin petemantx 07/16/18 10:36:39 PM
#226817  Sticky Note BP's interests in the Big Three sox040713 05/04/18 04:17:49 PM
#235053   No doubt MP was paid to write that scottsmith 07/22/18 08:27:32 PM
#235052   OK LR, kfcyahoo 07/22/18 08:22:38 PM
#235051   What ever happened to running girl?? Guess she's JTORENCE 07/22/18 08:14:09 PM
#235050   Echo if you are experiencing the torturous side JTORENCE 07/22/18 08:05:14 PM
#235049   MP Advisors out of India, I presume? Theye kfcyahoo 07/22/18 08:00:41 PM
#235048   Now your getting into needing USDA approval.ha Williamsc 07/22/18 07:19:45 PM
#235047   Echo is usually right about these things. scottsmith 07/22/18 07:16:05 PM
#235046   This is not a bowel cleanser or a Williamsc 07/22/18 07:04:45 PM
#235044   Do you think Meryl Streep might take a scottsmith 07/22/18 05:38:53 PM
#235043   "Special designations, such as Fast Track, Priority Review loanranger 07/22/18 05:19:15 PM
#235042   Actually, all signs point to B-OM being the hazelhurst 07/22/18 04:13:54 PM
#235041   Scottsmith 2 times I wrote or Echo20 07/22/18 03:57:41 PM
#235040   Scottsmith Flavors like spices can be very important. Some Echo20 07/22/18 03:52:43 PM
#235039   Rdunn88 So 100 and 200 mg doses came out Echo20 07/22/18 03:44:55 PM
#235038   Is IPIX the real deal? You bet! Not rmzport 07/22/18 02:59:25 PM
#235036   Leo spending money adding to the patent protection/expansion rmzport 07/22/18 02:31:01 PM
#235035   P stats from MP Advisors... Nice report from Rdunn88 07/22/18 02:25:41 PM
#235034   Georgejji Great total figures. If P is used by Echo20 07/22/18 01:44:59 PM
#235033   What flavor of Brilacidin do you believe President scottsmith 07/22/18 01:42:53 PM
#235032   slcimmuno Sunday, 06/25/17 10:53:51 PM rmzport 07/22/18 01:41:42 PM
#235031   FlashingLeather Sunday, 06/25/17 07:52:12 PM rmzport 07/22/18 01:39:12 PM
#235030   Karincs Low costs to make P, B and K Echo20 07/22/18 01:38:28 PM
#235029   Errrrr AlanC ya gettin time and a half chris13 07/22/18 01:33:13 PM
#235028   That's it, Scotty, we can count on you MackG 07/22/18 01:31:42 PM
#235027   slcimmuno Tuesday, 06/20/17 11:21:31 PM rmzport 07/22/18 01:23:12 PM
#235026   cabel Wednesday, 05/10/17 09:02:58 PM rmzport 07/22/18 01:18:41 PM
#235025   Karin, I agree that Brilacidin ABSSSI was not Empiricst1 07/22/18 12:56:50 PM
#235024   Hopefully not a post mortem piece. scottsmith 07/22/18 12:40:40 PM
#235023   Fantastic article. Looking forward to the next Cherry_11 07/22/18 12:01:52 PM
#235021   Edit... just checked and both are already unlocked. KarinCA 07/22/18 10:42:25 AM
#235020   Thanks for nipping that “Brilacidin was shelved...” notion TheDane 07/22/18 10:36:45 AM
#235019   Looks like SA is charging for your article. GAB 07/22/18 10:21:26 AM
#235018   Thanks George snayeman 07/22/18 10:20:55 AM
#235017   I'm thinking that what you are referring to KarinCA 07/22/18 10:15:51 AM
#235016   Even if the cost is 1/2 your figure, JUST 10-11-12 07/22/18 09:47:27 AM
#235015   snayeman NO!eom JTORENCE 07/22/18 09:46:02 AM
#235014   George, p news this week? snayeman 07/22/18 09:43:03 AM
#235013   For someone with severe psoriasis a ≥ 2 georgejjl 07/22/18 09:28:13 AM
#235012   Did they cover? No, they did not AlanC 07/22/18 09:23:25 AM
#235011   If 7.5 million people in the USA alone georgejjl 07/22/18 09:07:37 AM
#235010   You do the math. If the cost of georgejjl 07/22/18 08:53:25 AM
#235009   Statistics related to psoriasis georgejjl 07/22/18 08:46:25 AM
#235008   Would like to know a bit more about scottsmith 07/22/18 08:46:20 AM
#235007   "And they all lose their effects over time" loanranger 07/22/18 07:54:39 AM
#235006   "Here’s another company who did the same." loanranger 07/22/18 07:25:30 AM
#235005   Msybe we are neighbors? scottsmith 07/22/18 06:56:40 AM
#235004   Basil, I agree with your post, but there Empiricst1 07/22/18 04:27:17 AM
#235003   Leo & Sullivan decided to change the CUSIP sox040713 07/22/18 03:20:51 AM
#235002   Either Leo is incompetent or he knows B Basil22 07/22/18 01:10:11 AM
#235000   IPIX Milestones, Clinical Trials, Recent Articles, Corporate Overview, Patent sox040713 07/21/18 11:52:18 PM
PostSubject